Problem

NeuroDiscovery AI addresses two linked bottlenecks in neurological drug development: recruiting eligible patients into clinical trials and turning fragmented clinical information into usable real-world data and evidence. The company describes a neurology recruitment crisis in which conventional approaches can take 6–18 months to fill a trial, creating empty sites, timeline delays, and the associated cost of keeping studies and research operations running while enrollment lags. Its central use case is shortening the path from a trial protocol to a qualified, screening-ready patient cohort.

The company’s stated “1:1:1 Guarantee” illustrates that use case: identify the relevant cohort in one day, begin patient outreach within one week, and produce screening-ready patients within one month. Beyond recruitment, the same data infrastructure is intended to help life-sciences companies analyze treatment patterns, disease progression, and outcomes without waiting for conventional prospective studies to generate all the evidence they need.

Product / Service

NeuroDiscovery AI presents a business-to-business, neurology-specialized AI and data platform for pharmaceutical, biotechnology, healthcare, and research organizations. Its proprietary NeuroLLM is designed for pharmaceutical applications and combines EHR, billing and claims, laboratory, imaging, genetic, EEG, EMG, and other multimodal information; the company says the model is trained on more than 5 million U.S. neurology patient records and more than 400 million images. Knowledge graphs, predictive analytics, imaging models, topological data analysis, and multi-omics integration are used to identify patterns, biomarkers, drug targets, and treatment outcomes.

The delivery model combines access to the underlying neurological dataset with managed clinical-trial recruitment and real-world evidence services. Life-sciences customers can use the platform to identify and contact trial candidates, obtain real-world data, accelerate drug discovery and development, and generate evidence intended to support regulatory submissions. The practical benefit is a specialized data-and-AI layer built around neurology rather than a general-purpose model, with access supplied through the company’s provider and research partnerships.

Market

The company competes at the intersection of AI-enabled clinical-trial recruitment, neurological real-world data and real-world evidence, and life-sciences analytics. Directly comparable recruitment platforms named in the available company-profile evidence include Inato, Trially, AutoCruitment, and SubjectWell; Inato is also described as using AI to prescreen patients for trial eligibility. In the broader RWE category, larger established players include IQVIA, Optum, Flatiron Health, Oracle, and Parexel, although NeuroDiscovery AI differentiates itself through its neurology specialization and multimodal neurological dataset.

The available evidence indicates an operating, partnership-led company rather than a purely pre-launch concept. NeuroDiscovery AI claims relationships with more than 470 U.S. neurology providers, data covering more than 5 million patients and 1.5 million active patients, a partnership with First Choice Neurology, and a pharma-collaborated poster presented at ADPD 2026. Financial traction is less certain: PitchBook reports $6 million raised, while Tracxn says no funding has been raised, and a May 2026 report described a proposed $100 million–$150 million raise alongside projected—not verified—2026 ARR of approximately $14 million. Thus, commercial activity and strategic traction are evident, but audited revenue and financing should be treated as unverified in this evidence set.